Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

Article  PubMed  Google Scholar 

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, ... & Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644.

Ruers T, Van Coevorden F, Punt CJ, Pierie JPE, Borel-Rinkes I, Ledermann JA, ... & Nordlinger B. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. JNCI: Journal of the National Cancer Institute. 2017;109(9):djx015.

Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, ... & Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578.

Gruenberger T, Bridgewater J, Chau I, Alfonso PG, Rivoire M, Mudan S, ... & Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–708.

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):e170278–e170278.

Article  PubMed Central  Google Scholar 

Ychou M, Rivoire M, Thezenas S, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289–97.

Article  PubMed  Google Scholar 

Cremolini, C. H. I. A. R. A., Loupakis, F. O. T. I. O. S., Antoniotti, C. A. R. L. O. T. T. A., Lonardi, S., Masi, G., Salvatore, L., ... & Falcone, A. L. F. R. E. D. O. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26(6):1188–1194.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, ... & Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, ... & Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New England J Med. 2014;371(17):1609–1618.

Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, ... & Ychou M. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first‐line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16(11):1557–1564.

Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, ... & Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103(10):1542–1547.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, ... & Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer. 2012;107(12):1932–1937.

Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, ... & Falcone A. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24(8):2062–2067.

Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, ... & Deng Y. Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild‐type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase II trial. Oncologist. 2012;26(1):e90-e98.

Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3401–11.

Swen Wessendorf MD, Thomas Ettrich MD, Stephan Kanzler MD, Dominik Nörenberg MD, Jens Ricke MD. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol. 2020;37:3401–11.

Google Scholar 

Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer. 2014;50(9):1590–601.

Article  PubMed  Google Scholar 

Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311–9.

Article  CAS  Google Scholar 

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, ... & Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, ... & Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.

ClinicalTrials. gov. Medicine. UNLo. 2014 https://clinicaltrials.govct2/show/NCT02063529.

ClinicalTrials. gov. Medicine. UNLo. 2015 https://clinicaltrials. gov/ct2/show/NCT02515734.

ClinicalTrials. gov. Medicine. UNLo. 2013 https://clinicaltrials.gov/ct2/show/NCT01802645.

ClinicalTrials. gov. Medicine. UNLo. 2011 https://clinicaltrials. gov/ct2/show/NCT01328171.